Presupernova evolution and explosive nucleosynthesis of zero metal massive stars

We present a new set of zero metallicity models in the range 13-80 $\rm M_\odot$ together to the associated explosive nucleosynthesis. These models are fully homogeneous with the solar metallicity set we published in Limongi & Chieffi (2006) and will be freely available at the web site http://www.iasf-roma.inaf.it./orfeo/public{\_}html. A comparison between these yields and an average star that represents the average behavior of most of the very metal poor stars in the range $\rm -5.0<[Fe/H]<-2.5$ confirms previous findings that only a fraction of the elemental [X/Fe] may be fitted by the ejecta of $\it standard$ core collapse supernovae.Comment: 39 pages, 8 figures, 2 tables, accepted for publication in ApJ

The metal and dust yields of the first massive stars

We quantify the role of Population (Pop) III core-collapse supernovae (SNe) as the first cosmic dust polluters. Starting from a homogeneous set of stellar progenitors with masses in the range [13 - 80] Msun, we find that the mass and composition of newly formed dust depend on the mixing efficiency of the ejecta and the degree of fallback experienced during the explosion. For standard Pop III SNe, whose explosions are calibrated to reproduce the average elemental abundances of Galactic halo stars with [Fe/H] < -2.5, between 0.18 and 3.1 Msun (0.39 - 1.76 Msun) of dust can form in uniformly mixed (unmixed) ejecta, and the dominant grain species are silicates. We also investigate dust formation in the ejecta of faint Pop III SN, where the ejecta experience a strong fallback. By examining a set of models, tailored to minimize the scatter with the abundances of carbon-enhanced Galactic halo stars with [Fe/H ] < -4, we find that amorphous carbon is the only grain species that forms, with masses in the range 2.7 10^{-3} - 0.27 Msun (7.5 10^{-4} - 0.11 Msun) for uniformly mixed (unmixed) ejecta models. Finally, for all the models we estimate the amount and composition of dust that survives the passage of the reverse shock, and find that, depending on circumstellar medium densities, between 3 and 50% (10 - 80%) of dust produced by standard (faint) Pop III SNe can contribute to early dust enrichment.Comment: Accepted by MNRAS, 22 pages, 12 figures, 12 table

Pre-suprenova evolution of rotating massive stars

The Geneva evolutionary code has been modified to study the advanced stages (Ne, O, Si burnings) of rotating massive stars. Here we present the results of four 20 solar mass stars at solar metallicity with initial rotational velocities of 0, 100, 200 and 300 km/s in order to show the crucial role of rotation in stellar evolution. As already known, rotation increases mass loss and core masses (Meynet and Maeder 2000). A fast rotating 20 solar mass star has the same central evolution as a non-rotating 26 solar mass star. Rotation also increases strongly net total metal yields. Furthermore, rotation changes the SN type so that more SNIb are predicted (see Meynet and Maeder 2003 and N. Prantzos and S. Boissier 2003). Finally, SN1987A-like supernovae progenitor colour can be explained in a single rotating star scenario.Comment: To appear in proceedings of IAU Colloquium 192, "Supernovae (10 years of 1993J)", Valencia, Spain 22-26 April 2003, eds. J.M. Marcaide, K.W. Weiler, 5 pages, 8 figure

Role of glutathionylation in infection and inflammation

Glutathionylation, that is, the formation of mixed disulfides between protein cysteines and glutathione (GSH) cysteines, is a reversible post-translational modification catalyzed by dierent cellular oxidoreductases, by which the redox state of the cell modulates protein function. So far, most studies on the identification of glutathionylated proteins have focused on cellular proteins, including proteins involved in host response to infection, but there is a growing number of reports showing that microbial proteins also undergo glutathionylation, with modification of their characteristics and functions. In the present review, we highlight the signaling role of GSH through glutathionylation, particularly focusing on microbial (viral and bacterial) glutathionylated proteins (GSSPs) and host GSSPs involved in the immune/inflammatory response to infection; moreover, we discuss the biological role of the process in microbial infections and related host responses

On the Origin of the Early Solar System Radioactivities. Problems with the AGB and Massive Star Scenarios

Recent improvements in stellar models for intermediate-mass and massive stars are recalled, together with their expectations for the synthesis of radioactive nuclei of lifetime $\tau \lesssim 25$ Myr, in order to re-examine the origins of now extinct radioactivities, which were alive in the solar nebula. The Galactic inheritance broadly explains most of them, especially if $r$-process nuclei are produced by neutron star merging according to recent models. Instead, $^{26}$Al, $^{41}$Ca, $^{135}$Cs and possibly $^{60}$Fe require nucleosynthesis events close to the solar formation. We outline the persisting difficulties to account for these nuclei by Intermediate Mass Stars (2 $\lesssim$ M/M$_\odot \lesssim 7 - 8$). Models of their final stages now predict the ubiquitous formation of a $^{13}$C reservoir as a neutron capture source; hence, even in presence of $^{26}$Al production from Deep Mixing or Hot Bottom Burning, the ratio $^{26}$Al/$^{107}$Pd remains incompatible with measured data, with a large excess in $^{107}$Pd. This is shown for two recent approaches to Deep Mixing. Even a late contamination by a Massive Star meets problems. In fact, inhomogeneous addition of Supernova debris predicts non-measured excesses on stable isotopes. Revisions invoking specific low-mass supernovae and/or the sequential contamination of the pre-solar molecular cloud might be affected by similar problems, although our conclusions here are weakened by our schematic approach to the addition of SN ejecta. The limited parameter space remaining to be explored for solving this puzzle is discussed.Comment: Accepted for publication on Ap

Drug delivery applications of three-dimensional printed (3DP) mesoporous scaffolds

Mesoporous materials are structures characterized by a well-ordered large pore system with uniform porous dimensions ranging between 2 and 50 nm. Typical samples are zeolite, carbon molecular sieves, porous metal oxides, organic and inorganic porous hybrid and pillared materials, silica clathrate and clathrate hydrates compounds. Improvement in biochemistry and materials science led to the design and implementation of different types of porous materials ranging from rigid to soft two-dimensional (2D) and three-dimensional (3D) skeletons. The present review focuses on the use of three-dimensional printed (3DP) mesoporous scaffolds suitable for a wide range of drug delivery applications, due to their intrinsic high surface area and high pore volume. In the first part, the importance of the porosity of materials employed for drug delivery application was discussed focusing on mesoporous materials. At the end of the introduction, hard and soft templating synthesis for the realization of ordered 2D/3D mesostructured porous materials were described. In the second part, 3DP fabrication techniques, including fused deposition modelling, material jetting as inkjet printing, electron beam melting, selective laser sintering, stereolithography and digital light processing, electrospinning, and two-photon polymerization were described. In the last section, through recent bibliographic research, a wide number of 3D printed mesoporous materials, for in vitro and in vivo drug delivery applications, most of which relate to bone cells and tissues, were presented and summarized in a table in which all the technical and bibliographical details were reported. This review highlights, to a very cross-sectional audience, how the interdisciplinarity of certain branches of knowledge, as those of materials science and nano-microfabrication are, represent a growing valuable aid in the advanced forum for the science and technology of pharmaceutics and biopharmaceutics